For institutions that do not perform rapid on-site evaluation (ROSE) or have challenges in their current ROSE offering during FNA procedures, ASP Health’s technology platform offers:
ASP Health Inc
- Home
- Companies
- ASP Health Inc
- Products
- ASP Health - ASP Health's Technology ...
ASP Health - ASP Health's Technology Platform
FromASP Health Inc
ASP Health's technology platform is designed to meet the evolving needs of institutions facing challenges in rapid on-site evaluation (ROSE) during fine needle aspiration (FNA) procedures. The platform focuses on improving the quality of samples to match or exceed current manual methods while automating the process to alleviate the workload of cytotechnologists. It also streamlines the entire sample preparation process, ensuring it does not extend the duration of patient's anesthesia. The system ensures consistency in sample preparation, standardizes protocols, and enhances workflow efficiency. With AI compatibility, it aims to improve cancer detection and evaluation. The technology also maintains meticulous custody of clinically important specimens, which can be used for future molecular and genetic testing, ultimately guiding therapeutic decisions. ASP Health addresses the national shortage of cytopathologists and cytotechnologists, especially in rural areas, by offering a cost-effective and automated solution that could potentially save many lives. ASP Health is also committed to broad intellectual property protection, with multiple patents filed. The platform has FDA registration as a Class 1 device and meets safety standards verified by Underwriters Laboratories. The company plans to collaborate with commercial partners to roll out its automated ROSE system nationwide.Most popular related searches
sample preparation
sample preparation system
automated sample preparation system
automatic sample preparation system
sample preparation regulations
autosampling
process automation
automatic sample preparation
sample automation
contaminant sampling
Our ASP System is ROSE ready* and is based on a series of innovations guided by extensive market research that identified the need for:
- a mobile, automated instrument with a simple and intuitive user interface.
- requisite consumables to reduce the risk of sample contamination.
- retention of remaining sample in a collection jar for future evaluation.
- the ability to complete the entire process in under two minutes.
Quality
samples that are equal to or better than current manual processes;
Automation
to reduce the pressure on cytotechnologists that prepare samples manually during a patient procedure;
Efficient Process
to ensure sample preparation does not prolong the physician’s FNA procedure and the patient’s time under anesthesia;
Consistency/
Standardization
to reduce the variability in sample preparation and to standardize protocols to enhance patient safety and workflow efficiency.
AI Compatibility
to enhance the evaluation and detection of cancer;
Sample Custody
of clinically important specimens separated into individual collection vials for future molecular/genetic testing to guide downstream patient therapy.
Interventional Pulmonologists:
“ROSE is the new standard; we could use better and faster devices in our O.R.s and other settings to meet the demand for FNAs and shorten procedure times”
Cytopathologists:
“Producing consistent standardized samples quickly would reduce stress on our cytotechnologists”
Futurists:
“Consistent automated samples will lead to remote and automated reading of these specimen slides as well as expansion to other opportunities”
The current national shortage of cytopathologists and cytotechnologists, particularly in rural areas, significantly limits the number of institutions that can perform ROSE. Our automated technology provides a cost-effective solution to this problem, a solution that will help more people survive cancer.
Phased Rollout:
Our initial focus is on the successful development and pilot commercialization of the automated ROSE sample preparation system using ASP Health’s proprietary technology platform. Additional instruments and tools to enhance evaluations in the pathology lab will follow.
Intellectual Property:
ASP Health is establishing broad coverage of its intellectual property rights through design and utility patents for its instrument and disposables, and for future software applications. Currently, we have five patent applications and two provisional patents submitted.
Regulatory:
As a Class 1 device, our technology is already registered with the U.S. Food and Drug Administration (FDA) and its safety has been tested by Underwriters Laboratories (UL).
Partnership:
We intend to partner with a commercial company that has the reach to successfully implement ASP Health’s ROSE system nationwide and support the long-term mission of the company.
Reimbursement:
The ROSE procedure is already covered under existing codes; new coding for our platform is not needed.